Summary Latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H1 2020, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1 and 6 respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall.

Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 3, 7, 1, 36, 13 and 2 respectively.

Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Summary Latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2020, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.

"Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis.

" Report Highlights Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 2 respectively.

Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Summary This report is the 10th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance.

CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.

Scope This report is required reading for -- CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions.- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.Reasons to Buy - Overview of NDA drug approvals and the levels of outsourcing associated with NDA sub segments- Detailed view of CDMO performance by number of approvals and an assessment of their sponsors market caps from GlobalData's Contract Service Providers database- Outsourcing propensity for NMEs, different dosage forms and by sponsor company cap have all been assessed.- Analysis of NME special products approvals such as those with Orphan, Breakthrough or Fast Track designations and assessment of outsourcingGet the Complete Report & TOC @ https://www.primemarketreports.com/reports/2917/cmo-scorecardoutsourcing-of-nda-approvals-cmo-performance-edition-2020-187Table of content1 Table of Contents2 List of Tables3 List of Figures4 Executive Summary5 Introduction6 FDA NDA Approvals Overview7 US vs. EU Approval Performance8 FDA: Outsourced Dose Manufacture9 Special Product Categories10 Outsourcing by Company Market Cap11 CMO Performance11.1 Catalent11.2 Patheon11.3 Other Prominent CMOs12 Outsourced API Approvals13 What It Means13.1 FDA Approvals Have Fallen but Are Still Strong Compared to Historical Standards13.2 Drivers and Barriers for Outsourcing13.2.1 Niche Technology13.2.2 Small Volumes, Special Designations13.2.3 Sponsor Market Cap Relationships to Outsourcing14 Notes on Methodology15 Appendix15.1 Appendix Tables15.2 Bibliography15.3 Primary Research - Key Opinion Leaders in this Report15.4 About the Authors15.5 Contact Us15.6 DisclaimerCONTACT US:North Main Road Koregaon Park, Pune, India - 411001.International: +1(646)-781-7170Asia: +91 9169162030Email: [email protected]

Summary Latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H1 2020, provides an overview of the Ureter Cancer (Oncology) pipeline landscape.

Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Ureter Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ureter Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 9 and 6 respectively.

Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.

Ureter Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Summary Latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020, provides an overview of the Organophosphate and Carbamate Poisoning (Other Diseases) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Organophosphate and Carbamate Poisoning (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Summary Latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.

Causes include cardiomyopathy, ischemic heart disease and heart failure.

Report Highlights Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from We are proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Summary As digitization continues to shape customers’ attitudes and purchasing behaviors, insurers are being forced to rethink their distribution models and put a greater focus on the direct channel.

Established players have the largest market shares for direct sales, but new entrants have focused their efforts on the direct channel and have excelled at removing friction from the customer journey.

This is helping them differentiate their brands.

Most insurers continue to hold strong ties with intermediaries, but the prospect of improved margins will incentivize them to continue investing in the direct channel.

This report explores how the insurance industry has evolved from selling products almost solely via brokers and other intermediaries to more direct methods as consumers become increasingly connected.

It highlights which business lines have been most commoditized, rendering them more suitable for direct and unadvised sales.

Summary latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

The airflow to the lungs is further blocked.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 8, 38, 15, 3, 77, 21 and 5 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Summary Latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H1 2020, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.

Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4 and 1 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Summary Latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2020, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.

Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 3, 1 and 4 respectively.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Summary Ring Inc. (Ring) is a smart home solutions company that offers home security products.

The company manufactures connected devices for homes and helps secure even neighborhoods.

Scope The report provides information and insights into Ring's, including -- Overview of the company and its product offering- Detailed insight into its business model, company type and headquarter- Information on funding- Biography of top managementReasons to Buy - Gain insights into Ring’s business operations.- Gain insights into funding and partnerships- Gain understanding about its technology focus.Get the Complete Report & TOC @ https://www.primemarketreports.com/reports/2858/ring-inc-tech-innovator-148Table of contentTable of ContentsCompany OverviewTechnology FocusProduct OverviewPartnership & FundingKey EmployeesAppendixCONTACT US:North Main Road Koregaon Park, Pune, India - 411001.International: +1(646)-781-7170Asia: +91 9169162030Email: [email protected]

Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss.

Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain.

Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease Peripheral Vascular Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 8, 2, 12, 3 and 2 respectively.

Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra.

Symptoms generally develop slowly over years.

Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

Report Highlights We are Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 47, 58, 4, 212, 90 and 9 respectively.

Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 51 and 15 molecules, respectively.

Summary 23andMe, Inc. (23andMe) is a personal genomics and biotechnology company that leverages machine learning (ML) technology to provide DNA analysis services.

Scope The report provides information and insights into 23andMe, Inc.'s, including -- Overview of the company and its product offering- Detailed insight into its business model, company type and headquarter- Information on funding- Biography of top managementReasons to Buy - Gain insights into 23andMe’s business operations.- Gain insights into funding and partnerships- Gain understanding about its technology focus.Get the Complete Report & TOC @ https://www.primemarketreports.com/reports/2856/me-inc-tech-innovator-724Table of contentTable of ContentsCompany OverviewTechnology FocusProduct OverviewPartnerships & FundingKey EmployeesAppendixCONTACT US:North Main Road Koregaon Park, Pune, India - 411001.International: +1(646)-781-7170Asia: +91 9169162030Email: [email protected]